SEC Form 4 · accession 0001237899-15-000029
REGENERON PHARMACEUTICALS, INC. · REGN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Joseph J Larosa
Officer — SVP General Counsel and Secret
Period of report
Mar 25, 2015
Accepted (ET)
Mar 26, 2015 · 4:21 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000872589
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Mar 25, 2015 | M | 3,097 | $59.20 | A | 15,067 | D | |
| Common Stock | holding | — | — | — | 120 | I | By 401(k) Plan |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Incentive Stock Option (right to buy)F1 | $59.20 | Mar 25, 2015 | M | 3,097 | D | — | Sep 1, 2021 | Common Stock | 3,097 | 1,689 | D |
Explanation of responses
- F1The stock option award (combined incentive stock option and non-qualified stock option) vests in four equal annual installments, commencing one year after the date of grant.